About US
Contact us
-
FDA scrutinizing Merck's Januvia, BMS' ByettaThe FDA is taking a closer look at the increased risk of Type 2 diabetics getting pancreatic cancer from the popular drugs like Merck's blockbuster Januvia and Byetta from Bristol-Myers Squibb. The2013/3/15
-
Sistemic and Leading CDMO, Progenitor Cell Therapy (PCT) Initiate Study on Novel Stem Cell Characterisation TechnologySistemic Limited (Sistemic), the miRNA profiling company with facilities in Glasgow, Scotland and Boston, announced today the signature of an agreement to allow Progenitor Cell Therapy (PCT), Mountai2013/3/14
-
Pfizer's popular 'Z-Pak' carries increased fatal risk for some, FDA saysThe "Z-Pak" is a convenient and so a popular antibiotic treatment that doctors prescribe for everything from ear infections to pneumonia. But in case anybody missed it earlier, the FDA wants to make2013/3/14
-
Big Pharma puts funds into Interpol effort to thwart counterfeitersBig Pharma sees drug counterfeiting as a major problem as international criminals find new ways to get fake drugs, even counterfeit cancer meds, into the legitimate supply chain. Now more than two do2013/3/13
-
Cancer Genetics, Inc. Selected By Gilead Sciences, Inc. to Provide Clinical Trial Services for International Trials in ChronicCancer Genetics, Inc. (CGI) announces that it has been chosen by Gilead Sciences Inc. (Gilead) to provide clinical trial services and molecular profiling of chronic lymphocytic leukemia (CLL) patient2013/3/13
-
Drug formulation developer Dyax announces board changesDrug formulation developer Dyax Corp has announced the departure of its executive vice president chief operating officer. Ivana Magovcevic-Liebisch PhD JD is leaving to pursue a senior management2013/3/12
-
DoJ probes Sanofi disclosures on Plavix effectivenessIt's common knowledge now that the Plavixblood thinner is less effective in certain patients. But when did Sanofi ($SNY) know that its star drug didn't work so well in those people? Did the French dr2013/3/12
-
Patheon's Banner buyout adds to lossesPatheon's $255 million buyout last year of Mexico's Banner Pharmacaps gave the contract manufacturer a beachhead in the fast-growing Latin American market. But it lost something along the way. The No2013/3/11
-
UPDATED: Bayer, J&J test Xarelto uses, even as ACS indication eludesJohnson & Johnson ($JNJ) and Bayer AG are looking on the bright side of things when it comes to Xarelto. They are undertaking new trials they hope will lead to much wider use of the new kind of b2013/3/11
-
Activartis Receives Orphan Drug Designation for its Cancer Immune Therapy AV0113The European Medicines Agency recently awarded the Austrian biotech company ctivartis an Orphan Drug Designation for its innovative Cancer Immune Therapy AV0113. The Orphan Drug Designation applies s2013/3/8